NEWS
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings from regular abstracts include:
Imdusiran with interferon treatment showed distinct phases of immune biomarker signatures, with Th1 activation during imdusiran lead-in and Th2 signatures associated with HBsAg seroconversion.
The imdusiran target site is highly conserved in cHBV subjects, with in vitro testing confirming activity against tested variants.
Imdusiran is designed to reduce all HBV viral proteins and antigens, potentially enabling immune system reawakening. It is currently in multiple Phase 2a clinical trials.
Key findings from regular abstracts include:
Imdusiran with interferon treatment showed distinct phases of immune biomarker signatures, with Th1 activation during imdusiran lead-in and Th2 signatures associated with HBsAg seroconversion.
The imdusiran target site is highly conserved in cHBV subjects, with in vitro testing confirming activity against tested variants.
Imdusiran is designed to reduce all HBV viral proteins and antigens, potentially enabling immune system reawakening. It is currently in multiple Phase 2a clinical trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2628Followers
107Following
28KVisitors
Follow